Search research articles
Contact Us
Filters
Showing results (11-20 of 129) with videos related to
Page
of 13
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 20, 2015
Are Doses and Schedules of Small-Molecule Targeted Anticancer Drugs Recommended by Phase I Studies Realistic?
Desamparados Roda, Begoña Jimenez, Udai Banerji
Biotechniques
|
July 11, 2025
An enzyme-free alcohol-based organoid harvesting solution
Jimmy Maillard, Lisa Pickard, Udai Banerji
Current Drug Targets
|
September 15, 2012
Tissue-based approaches to study pharmacodynamic endpoints in early phase oncology clinical trials
Joo Ern Ang, Stan Kaye, Udai Banerji
European Journal of Cancer (Oxford, England : 1990)
|
October 11, 2019
Deep and sustained radiological response after MEK-RAF inhibition in HRAS mutant apocrine carcinoma of the scalp
Mariana Scaranti, Daniel Nava Rodrigues, Udai Banerji
Nature Biotechnology
|
July 12, 2012
Combinatorial drug therapy for cancer in the post-genomic era
Bissan Al-Lazikani, Udai Banerji, Paul Workman
Nature Reviews. Clinical Oncology
|
March 11, 2020
Exploiting the folate receptor α in oncology
Mariana Scaranti, Elena Cojocaru, Susana Banerjee, et al.
Molecular Cancer Therapeutics
|
April 1, 2008
BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors
Udai Banerji, Annette Affolter, Ian Judson, et al.
Cancer Treatment Reviews
|
June 18, 2023
Clinical trial designs for evaluating and exploiting cancer evolution
Alvaro H Ingles Garces, Nuria Porta, Trevor A Graham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 4, 2016
Biopsy-Derived Biomarkers in Phase I Trials: Building Confidence in Drug Development
Timothy A Yap, Udai Banerji, Johann S de Bono, et al.
Cancer Treatment Reviews
|
July 7, 2023
Corrigendum to "Clinical trial designs for evaluating and exploiting cancer evolution" [Cancer Treat. Rev. 118 (2023) 101583]
Alvaro H Ingles Garces, Nuria Porta, Trevor A Graham, et al.
Page
of 13
Search research articles
Search
Showing results (11-20 of 129) with videos related to
Sort By:
Page
of 13
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 20, 2015
Are Doses and Schedules of Small-Molecule Targeted Anticancer Drugs Recommended by Phase I Studies Realistic?
Desamparados Roda, Begoña Jimenez, Udai Banerji
Biotechniques
|
July 11, 2025
An enzyme-free alcohol-based organoid harvesting solution
Jimmy Maillard, Lisa Pickard, Udai Banerji
Current Drug Targets
|
September 15, 2012
Tissue-based approaches to study pharmacodynamic endpoints in early phase oncology clinical trials
Joo Ern Ang, Stan Kaye, Udai Banerji
European Journal of Cancer (Oxford, England : 1990)
|
October 11, 2019
Deep and sustained radiological response after MEK-RAF inhibition in HRAS mutant apocrine carcinoma of the scalp
Mariana Scaranti, Daniel Nava Rodrigues, Udai Banerji
Nature Biotechnology
|
July 12, 2012
Combinatorial drug therapy for cancer in the post-genomic era
Bissan Al-Lazikani, Udai Banerji, Paul Workman
Nature Reviews. Clinical Oncology
|
March 11, 2020
Exploiting the folate receptor α in oncology
Mariana Scaranti, Elena Cojocaru, Susana Banerjee, et al.
Molecular Cancer Therapeutics
|
April 1, 2008
BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors
Udai Banerji, Annette Affolter, Ian Judson, et al.
Cancer Treatment Reviews
|
June 18, 2023
Clinical trial designs for evaluating and exploiting cancer evolution
Alvaro H Ingles Garces, Nuria Porta, Trevor A Graham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 4, 2016
Biopsy-Derived Biomarkers in Phase I Trials: Building Confidence in Drug Development
Timothy A Yap, Udai Banerji, Johann S de Bono, et al.
Cancer Treatment Reviews
|
July 7, 2023
Corrigendum to "Clinical trial designs for evaluating and exploiting cancer evolution" [Cancer Treat. Rev. 118 (2023) 101583]
Alvaro H Ingles Garces, Nuria Porta, Trevor A Graham, et al.
Page
of 13